Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EBITDA (2022 - 2025)

Historic EBITDA for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$4.3 million.

  • Atara Biotherapeutics' EBITDA rose 8033.65% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.4 million, marking a year-over-year increase of 11763.71%. This contributed to the annual value of -$85.2 million for FY2024, which is 6893.82% up from last year.
  • Per Atara Biotherapeutics' latest filing, its EBITDA stood at -$4.3 million for Q3 2025, which was up 8033.65% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' EBITDA ranged from a high of $38.0 million in Q1 2025 and a low of -$89.6 million during Q1 2022
  • Over the past 4 years, Atara Biotherapeutics' median EBITDA value was -$31.6 million (recorded in 2024), while the average stood at -$36.9 million.
  • As far as peak fluctuations go, Atara Biotherapeutics' EBITDA tumbled by 49912.06% in 2023, and later skyrocketed by 22024.81% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' EBITDA (Quarter) stood at -$73.7 million in 2022, then rose by 18.45% to -$60.1 million in 2023, then skyrocketed by 78.85% to -$12.7 million in 2024, then surged by 66.15% to -$4.3 million in 2025.
  • Its last three reported values are -$4.3 million in Q3 2025, $2.4 million for Q2 2025, and $38.0 million during Q1 2025.